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Abstract
Backround: The emergence of Mycobacterium tuberculosis strains resistant to antituberculosis
agents has recently received increased attention owing largely to the dramatic outbreaks of multi
drug resistance tuberculosis (MDR-TB).
Methods: Patients residing in Zonguldak and Kayseri provinces of Turkey with, pulmonary
tuberculosis diagnosed between 1972 and 1999 were retrospectively identified. Drug susceptibility
tests had been performed for isoniazid (INH), rifampin (RIF), streptomycin (SM), ethambutol (EMB)
and thiacetasone (TH) after isolation by using the resistance proportion method.
Results: Total 3718 patients were retrospectively studied. In 1972–1981, resistance rates for to
SM and INH were found to be 14.8% and 9.8% respectively (n: 2172). In 1982–1991 period,
resistance rates for INH, SM, RIF, EMB and TH were 14.2%, 14.4%, 10.5%, 2.7% and 2.9% (n: 683),
while in 1992–1999 period 14.4%, 21.1%, 10.6%, 2.4% and 3.7% respectively (n: 863). Resistance
rates were highest for SM and INH in three periods. MDR-TB patients constituted 7.3% and 6.6%
of 1982–1991 and 1992–1999 periods (p > 0.05).
Conclusion: This study demonstrates the importance of resistance rates for TB. Continued
surveillance and immediate therapeutic decisions should be undertaken in order to prevent the
dissemination of such resistant strains.
Background
Infection with Mycobacterium tuberculosis is a current glo-
bal health problem [1]. Following a constant decrease in
the attack rate of this disease in developed countries dur-
ing the past decades, a marked increase in its incidence
has been recently recognized worldwide [1,2]. The emer-
gence of multiple drug resistant tuberculosis (MDR-TB) is
of great concern. Epidemiological studies for the assess-
ment of local resistance rates and the detection of MDR-
TB are therefore crucial in order to optimize empiric drug
therapy and to prevent the dissemination of resistant
strains in the community.
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berculosis agents has recently received increased attention
owing largely to the dramatic outbreaks of MDR-TB [1,3].
These outbreaks have been characterized by delayed diag-
noses, inadequate treatment regimens, high mortality,
and significant rates of nosocomial transmission [4]. Drug
resistance may occur, the latter as a result of inappropriate
regimens prescribed by providers, or of non-compliance
by patients [5].
Our aim was to study the prevalence of MDR-TB cases and
the patterns of resistance to anti-TB drugs in two regions
of Turkey, to find out and the difference between three
decades, in 1972–1999.
Methods
The study was conducted in Zonguldak and Kayseri, the
northwest and central regions of Anatolia in Turkey, re-
spectively. TB cases registered to the Tuberculosis Dispen-
sary in Zonguldak and Tuberculosis Hospital in Kayseri
were enrolled to this retrospective study. TB control sys-
tem and health care system for TB referrals did not change
significantly in Turkey during the last 30 years except ther-
apeutic approach to these patients.
In 1996 treatment regimens have changed substantially
in; (1) allocation of multiple drug regimens and (2) utili-
zation of short-course supervised chemotherapy. This sur-
vey marks the disappearance of "conventional" 18-month
chemotherapy of TB disease with INH-RIF-SM or INH-
EMB. All programs now use shorter-course therapies of 6
to 9 mo in duration, except under "special" circumstances
that are usually related to poor compliance or initial drug
resistance.
Patients
All enrolled cases were adults who are older than 18 years
residing in Zonguldak and Kayseri provinces with culture-
proven M. tuberculosis disease diagnosed between 1972
and 1999. Data was broken down into three period cate-
gories and resistance rates at 10-year intervals were ana-
lyzed. Risk factors for drug resistance could not be
evaluated as there was insufficient data in the charts.
Characterization of mycobacterial isolates
The analyzed M. tuberculosis strains were isolated at the TB
Laboratory in central laboratory for the Zonguldak, Kay-
seri TB Hospital laboratory and the National Reference
Laboratory (Institute of Refik Saydam Hifzisihha) in An-
kara. The species identification of the isolates was based
on standard microbiological tests: colony morphology,
acid-fast staining, and biochemical tests [6].
Drug susceptibility testing
Culture positivity for M. tuberculosis for each patient had
been recorded in data files. Data regarding the source of
the culture as well as drug susceptibilities were obtained
from the archives. Identification of M. tuberculosis was per-
formed based on standard physical and biochemical char-
acteristics. Samples were inoculated on Lowenstein-
Jensen media and incubated at 37°C in 5–10% CO2 at-
mosphere for 8 weeks. Positive cultures were identified
following the guidelines of conventional methods [6].
Susceptibility tests were performed using the resistance
proportion method for INH, RIF, SM, EMB and TH;
strains were considered highly resistant if the same growth
was observed on Lowenstein-Jensen medium containing
the following drug concentrations, respectively: 0.2–1 µg/
ml, 40 µg/ml, 4 µg/ml, 2 µg/ml and 2–4 µg/ml. All suscep-
tibility analyses were performed in the same laboratories
for Zonguldak and Kayseri. To detect TB drug resistance
proportional method was used and it has not been
changed during study period (1972–1999).
Resistance in new cases (primary) was defined as in vitro
resistance in patients who did not have a history of anti-
TB treatment, while retreatment resistance (secondary)
was defined as in vitro resistance in patients previously
treated with any anti-TB medication.
Definition
The definition of MDR-TB cases recommended by WHO
and IUATLD is the pattern of drug resistance to at least
INH and RIF. Resistance to several agents except these
agents was referred to as poly drug resistance TB (PDR-TB)
[7].
Statistics
The statistical evaluations were done using SPSS 9.0 soft-
ware (SPSS Inc., Chicago, IL, USA). The results were given
as the percentage and prevalence, and were assessed by
Chi-square test. Significance was taken as a p value of
<0.05.
Results
Total number of TB patients included was 3718. Two-
thousand-seven-hundred-sixty-one culture proven TB cas-
es were registered in Zonguldak Tuberculosis Dispensary,
957 TB patients were registered in Kayseri Tuberculosis
Hospital. Patients were primarily men (74.5%) with a me-
dian age of 35 year (range: 20–78) in two regions.
Anti-TB drug susceptibility test results according to
number of drugs were given in Table 1. MDR-TB consti-
tutes 7.3% and 6.6% of all the isolates in 1982–1991 and
1992–1999 periods. But single drug resistance was higher
in 1992–1999.Page 2 of 5
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resistance rates were increased after 1992. TH resistance
rates were found to be higher in 1992–1999, but there was
statistically difference between two decades (p > 0.05).
RIF and EMB resistance rates were similar in 1982–1991
and 1992–1999 periods. (Table 2)
Among patients with at least one drug resistance high re-
sistance rates were reported for SM (16.2%) and INH
(11.6%). The resistance rates to at least one drug were in-
creased significantly between three periods (p < 0.05).
In Figure 3 totally primary and secondary drug resistance
were shown. There was significantly increasing in primary
and secondary resistance ratio in 1992–1999 period (p >
0.05).
Discussion
A third of the world's population is estimated to be infect-
ed with M. tuberculosis [8]. Recently MDR-TB has increased
from an occasional infection to outbreak proportions. The
WHO's global surveillance for anti-TB drug resistance
from 1994 to 1997 had reported high resistance to anti-TB
drugs in 35 countries including Argentina, Asia, the Do-
minican Republic, and the former Soviet Union. From
1998 to 1999 alone, there were repeated reports in the
medical literature of MDR-TB in countries like Australia,
Azerbaijan, Canada, Estonia, Ethiopia, Guatemala, Hun-
gary, India, Kenya, Korea, Russia, Scotland, Taiwan, Thai-
land, The Netherlands, and West Africa [9,10]. Although
MDR-TB patients are an epidemiologic threat to the com-
munity in Turkey [11], it is not easy to improve the man-
agement significantly.
One study evaluated the resistance of the microorganisms
to primary anti-TB drugs over the 21 years period in Tur-
key. It was found that 60.8% of the isolated strains were
susceptible, whereas 39.2% were resistant to at least one
drug. MDR-TB was found in 194 (5.8%) materials. Over
the 21 years period studied, total resistance to INH, RF
and SM were determined as 10.5%, 6.9% and 7.0%, re-
spectively [12]. The single drug resistance rate reported in
this study is much higher than in our survey (39.2% ver-
sus 25.0%). MDR-TB and INH resistance rates are approx-
imately correlating to our results, but SM and RIF's
resistance rates lower than our rates (Table 2).
Recently, Cohn et al performed a Medline search of the
worldwide literature between 1985 and 1994 for the re-
sults of antimicrobial susceptibility testing of M. tubercu-
Table 1: Drug resistance patterns according to number of drugs and MDR-TB status.
1972–1981 (n = 2172) 1982–1991 (n:683) 1992–1999 (n:863) 1972–1999 (n:3718)
Resistance n % n % n % n %
One drug 319 14.7 100 14,6 278 32,2 713 19,1
Two drugs 96 4,4 47 6,8 18 2,0 166 4,4
Three drugs - - 19 2,7 28 3,2 57 1,5
More than three drugs* - - 13 1,9 11 1,2 24 1,5
At least one drug 415 19.1 179 26,2 335 38,8 929 25,0
PDR-TB 108 5,0 29 4,2 0 0 137 3,7
MDR-TB* - - 50 7,3 57 6,6 107 6,9
* Susceptibility test to RIF, EMB and TH had been performed after 1982 (n: 1546)
Table 2: Total anti-tuberculosis drug resistance for the study period.
1972–1981 (n = 2172) 1982–1991 (n:683) 1992–1999 (n:863)
Drugs n % n % n %
SM 322 14.8 99 14.4 182 21.1
INH 213 9.8 97 14,2 125 14.4
RIF1 - - 72 10.5 92 10.6
EMB1 - - 19 2,7 21 2.4
TH1 - - 20 2.9 15 3.7
Total 535 24.6 179 26.2 335 38.8
1: Susceptibility test to RIF, EMB and TH had been performed after 1982 (n: 1546)Page 3 of 5
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MDR-TB were reported from Nepal (48%), Gujarat, India
(34%), New York City (30%), Bolivia, and Korea (15%
each). In our retrospective study, MDR-TB patients consti-
tuted 7.3% and 6.6% in 1982–1991 and 1992–1999 peri-
ods respectively and resistance rates to at least one drug
were 19.1%, 26.2% and 38.8% in three periods. MDR-TB
rate could not be calculated as data of RIF's resistance is
unavailable for 1972–1981 periods (Table 1). Additional-
ly, the data of one, two, three drug resistance rate in 1972–
1981 period compared to other two periods was insuffi-
cient because of different kinds of drug resistance were de-
tected.
According to the Centers for Disease Control and Preven-
tion, when INH resistance rates are > 4%, quadruple em-
piric therapy with INH, RIF, PZA and EMB or SM is
indicated [14,15]. As INH resistance rates were > 4% over-
all in both study periods, quadruple empiric therapy at
least is indicated for every suspected or diagnosed TB case
in our populations. In our study resistance rates to INH
were 11.6 % (Table 2) and resistance rates to SM were
16.2%. Thus in both regions SM should not be preferred
as the fourth drug of choice in four drug regimens. Instead
EMB might be chosen.
Both primary and secondary drug resistance may occur,
the latter as a result of inappropriate regimens prescribed
by providers, or of non-compliance by patients [5]. We
differentiate between primary and secondary resistance
totally in three periods (Figure 1). In a Mexican study pri-
mary resistance was found to be higher than previous re-
port. However, acquired resistance was similar [16]. In
our study primary and secondary resistance rates were
higher in 1992–1999 periods. The prevalence of primary
and secondary resistance in our country has been studied
[11,17]. Our data was similar with these Turkish reports.
However, secondary drug resistance is a measure of the
quality of a TB control program and should be vigorously
sought and reported. Continued surveillance in the next
few years is warranted.
In Turkey, the majority of the patients are diagnosed as be-
ing TB by a positive acid-fast bacilli stain and most of the
cases are confirmed by culture. Many patients have ade-
quate access to health care and health care facilities. How-
ever some of the regions of Turkey do not possess the
appropriate infrastructure (for example they are deficient
in trained staff or simply lack the appropriate microbio-
logic laboratories) to allow accurate and rapid isolation
and susceptibility testing. It is important to improve
microbiologic laboratories around the country as well as
expand resources and education in order to enhance the
quality of treatment programs for all patients. In this man-
ner, the incidence and development of drug resistant cases
may be decreased. Additionally, directly observed therapy
(DOT) is not available currently in Turkey, we think that
implementation of good programs might have played a
role in decrease in anti-TB drug resistance rates. A reason-
able solution would be to develop a national specialized
Figure 1
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unit or team for the treatment of MDR-TB, as recommend-
ed in the WHO guidelines for the management of drug-re-
sistant TB [18,19].
In conclusion, although MDR-TB patients are an epidemi-
ologic threat to the community, it is not easy to improve
their management significantly. Continued surveillance
and immediate therapeutic decisions should be undertak-
en in order to prevent the dissemination of such resistant
strains to the general population.
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